Background: Lung cancer is often detected in advanced stages and can benefit from biomarker testing to identify targeted therapeutics. The IMPACT-NSCLC study was designed to identify barriers to equitable biomarker testing for lung cancer patients and develop targeted interventions to help improve biomarker testing rates using a digital personal health record and AI-enabled analysis. Methods: IMPACT-NSCLC unites the O'Neal Comprehensive Cancer Center (UAB) and Novellia, a leading personal health record tool, in a two-part single-institution study of adult NSCLC patients. Novellia uses proprietary technology and AI-enabled services to help patients digitally collect retrospective health records from providers and track health records prospectively, offering researchers a novel method of collecting and evaluating longitudinal health data. Part 1 of the study involves a retrospective study of patients with advanced NSCLC, with advanced data modeling to identify barriers and predictive factors in biomarker testing. Part 2 focuses on developing, implementing, and evaluating targeted interventions based on Part 1’s findings with the goal of improving biomarker testing rates in both academic and community settings. Results: In Part 1, data were collected from 35 patients diagnosed with NSCLC from 2020-2024. Most were white (80.77%) and male (53.84%). Median age was 65 (range 51-79). Most received care at an academic (NCI-designated) cancer center (74.28%). Most were not on commercial insurance plans (85.71%), with the most common form being BCBS/Medicare B and Viva Medicare. Most patients had Stage IV NSCLC (82.85%). More patients received liquid NGS testing at diagnosis (91.42%) than tissue NGS testing at diagnosis (68.57%). Nearly all patients (82.85%) received combination therapy, such as pemetrexed, and pembrolizumab, following biomarker testing. Oncologists initiated treatment while biomarker testing results were pending or incomplete more often in non-academic settings (55.55% of cases) vs. academic settings (26.92%). Conclusions: The pilot analysis found that patients with NSCLC typically received biomarker testing at diagnosis, more often with liquid biopsy. However, oncologists, especially in non-academic settings, often started treatment before full biomarker testing was completed. Comprehensive biomarker testing was frequently not done at progression. Further analysis leveraging machine learning and advanced modeling of Part 1 data may reveal more predictive factors for these variations, guiding interventions in Part 2. Developing a scalable best-practice guide for comprehensive biomarker testing could improve health system efficiencies and outcomes for patients with NSCLC.